Format

Send to

Choose Destination
See comment in PubMed Commons below
J Dermatolog Treat. 2014 Oct;25(5):396-400. doi: 10.3109/09546634.2012.697986. Epub 2012 Sep 2.

Metastatic melanoma: results of 'classical' second-line treatment with cytotoxic chemotherapies.

Author information

1
Department of Medical Oncology, Centre Régional de Lutte Contre le Cancer Eugène Marquis , Rennes , France.

Abstract

BACKGROUND:

Metastatic melanoma is one of the most aggressive tumours, with a median survival that does not exceed 12 months. None of the cytotoxic first-line therapies have shown survival benefit in randomised clinical trials.

OBJECTIVE:

To describe clinical benefit of second-line cytotoxic chemotherapy in the second line of treatment for metastatic melanoma.

METHODS:

In a retrospective study, we analyse the outcome of patients with metastatic melanoma who had received two lines or more of cytotoxic treatments in four French dermato-oncology departments between 1999 and 2009.

RESULTS:

We describe the outcomes for 109 patients. Most of these patients received dacarbazine for the first line of chemotherapy and fotemustine for the second line of chemotherapy (67.0 and 64.2%, respectively). A clinical benefit was observed in 24.1% of the patients and overall survival was 4.1 months after the second-line treatment. At least 23.8% of patients suffered from grade 3 or 4 toxicities. The presence of more than two sites of metastasis and an M1c staging according to the AJCC classification represented negative predictive factors of clinical benefit.

CONCLUSION:

This study shows the modest benefit of a second line of cytotoxic chemotherapy in a nonselected population. If eligible, these patients should be proposed for ongoing clinical trials or for targeted therapies.

PMID:
22632465
DOI:
10.3109/09546634.2012.697986
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center